These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23360448)

  • 1. Development of κ opioid receptor antagonists.
    Carroll FI; Carlezon WA
    J Med Chem; 2013 Mar; 56(6):2178-95. PubMed ID: 23360448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
    Nygard SK; Hourguettes NJ; Sobczak GG; Carlezon WA; Bruchas MR
    J Neurosci; 2016 Sep; 36(38):9937-48. PubMed ID: 27656031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.
    Anderson RI; Becker HC
    Alcohol Clin Exp Res; 2017 Aug; 41(8):1402-1418. PubMed ID: 28425121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.
    Spetea M; Asim MF; Noha S; Wolber G; Schmidhammer H
    Curr Pharm Des; 2013; 19(42):7362-72. PubMed ID: 23448472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
    Carlezon WA; Krystal AD
    Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynorphin activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus.
    Chen Z; Tang Y; Tao H; Li C; Zhang X; Liu Y
    Neuropharmacology; 2015 Oct; 97():259-69. PubMed ID: 26056031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of kappa-opioid receptors in stress and anxiety-related behavior.
    Van't Veer A; Carlezon WA
    Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders.
    Limoges A; Yarur HE; Tejeda HA
    Front Syst Neurosci; 2022; 16():963691. PubMed ID: 36276608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.
    Clark SD
    Handb Exp Pharmacol; 2022; 271():525-546. PubMed ID: 33459877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.
    Tejeda HA; Wang H; Flores RJ; Yarur HE
    Handb Exp Pharmacol; 2022; 271():223-253. PubMed ID: 33580392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.
    Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F
    Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.
    McDermott CM; Schrader LA
    J Physiol; 2011 Jul; 589(Pt 14):3517-32. PubMed ID: 21606111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
    Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
    J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynorphin, stress, and depression.
    Knoll AT; Carlezon WA
    Brain Res; 2010 Feb; 1314():56-73. PubMed ID: 19782055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective kappa opioid antagonists for treatment of addiction, are we there yet?
    Helal MA; Habib ES; Chittiboyina AG
    Eur J Med Chem; 2017 Dec; 141():632-647. PubMed ID: 29107424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.
    Banks ML
    Handb Exp Pharmacol; 2020; 258():147-165. PubMed ID: 31463605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kappa-opioid ligands in the study and treatment of mood disorders.
    Carlezon WA; Béguin C; Knoll AT; Cohen BM
    Pharmacol Ther; 2009 Sep; 123(3):334-43. PubMed ID: 19497337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.
    Erikson CM; Wei G; Walker BM
    Neuropharmacology; 2018 Sep; 140():162-173. PubMed ID: 30075159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.